The phase III SONIA trial (NCT03425838) directly addressed this issue by comparing early (first-line) versus delayed (second-line) use of CDK4/6 inhibitors in patients with HR+/HER2− advanced breast cancer (Sonke et al., 2024). Here, HR is linked to breast carcinoma.